Opendata, web and dolomites

PillSense SIGNED

Accelerating market introduction of the first real-time diagnistic and monitoring device for upper gastrointestinal bleeding (UGIB)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PillSense" data sheet

The following table provides information about the project.

Coordinator
ENTERASENSE LIMITED 

Organization address
address: PENN ENGINEERING MERVUE BUSINESS AND TECHNOLOGY PA
city: GALWAY
postcode: H91D3T0
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙551˙437 €
 EC max contribution 2˙675˙756 € (75%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ENTERASENSE LIMITED IE (GALWAY) coordinator 1˙029˙831.00
2    FAKULTNI NEMOCNICE OSTRAVA CZ (OSTRAVA PORUBA) participant 632˙500.00
3    STERIPACK MEDICAL POLAND SP ZOO PL (JELCZ LASKOWICE) participant 554˙400.00
4    ANECTO LIMITED IE (GALWAY) participant 459˙025.00

Map

 Project objective

Upper gastrointestinal bleeding (UGIB) is a potentially life-threatening condition that affects approx. 2 million people annually in Europe and in the United States. Current UGIB diagnosis comprises a long and slow set of laboratory tests and culminates ultimately with an endoscopy which is the only conclusive mean for UGIB diagnosis. This results in an over usage of endoscopic resources every time there is a suspicion of a bleed. Clinical data shows that up to 60% of the time endoscopy and consequent hospital admission is not necessary. In addition, endoscopy is invasive, expensive (approx. €2433) and cannot deliver prolonged monitoring. Multi-disciplinary consortium led by EnteraSense are developing a disruptive technology ‘PillSense’ which enables real-time detection of UGIB and subsequent monitoring of high risk patients without the need of endoscopy. The product includes an ingestible capsule and an external receiver. The capsule contains an optical based sensor to detect bleeding in the upper gastrointestinal tract. EnteraSense development team has already proven the core technology through lab-testing and in-vivo clinical studies. Through this 24months FTI project, the consortium aims to optimise PillSense product design, gain regulatory approvals, develop a commercial scale manufacturing process and gain clinical approval through two stages in-human clinical trials. Successful development and commercialisation will enable consortium to generate revenues of €59million and a gross profit of €29million over five years- post commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PILLSENSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PILLSENSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

GoSafe (2019)

Restoring complete sensory ability for natural walking of amputees

Read More  

BIOSNAP (2019)

SMART, SUSTAINABLE & CONVENIENT UNIT DOSE PACKAGING

Read More  

Mag-ID (2019)

Magnetic identification

Read More